A window of opportunity trial evaluating safety and tolerability of the vandetanib-eluting radiopaque beads in patients with primary liver cancer and mCRC

Trial Profile

A window of opportunity trial evaluating safety and tolerability of the vandetanib-eluting radiopaque beads in patients with primary liver cancer and mCRC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Colorectal cancer; Liver cancer
  • Focus Adverse reactions
  • Acronyms VEROnA
  • Sponsors BTG
  • Most Recent Events

    • 11 Oct 2017 New trial record
    • 09 Oct 2017 According to a BTG media release, first patient has been treated in this trial. This trial is supported by the Cancer Research UK Experimental Cancer Medicines Centre and the UCL Cancer Institute and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Centres for this trial are University College London Hospitals NHS Foundation Trust and the Royal Free Hospital NHS Foundation Trust.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top